Alpidem is an anxiolytic drug from the imidazopyridine family, related to the more well known sleeping medication zolpidem. Unlike zolpidem however, alpidem does not produce sedative effects at normal doses, and is instead used specifically for the treatment of anxiety. It was approved for marketing in France in 1991 and was withdrawn fin 1994 and is not approved for marketing anywhere in the world. Alpidem has nanomolar binding affinity for both the central benzodiazepine receptor (CBR) and the peripheral benzodiazepine receptor (PBR) (translocator protein 18 kDa) (PBR (Ki ) 0.5-7 nM) and CBR (Ki ) 1-28 nM, respectively). References: Nair DK, Mobin SM, Namboothiri IN. Synthesis of imidazopyridines from the Morita-Baylis-Hillman acetates of nitroalkenes and convenient access to Alpidem and Zolpidem. Org Lett. 2012 Sep 7;14(17):4580-3. doi: 10.1021/ol3020418. Epub 2012 Aug 24. PubMed PMID: 22920993.

纯度：≥98%

CAS：82626-01-5